Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.
OBJECTIVE
Intravitreal injections can cause several ocular complications, including vitreous hemorrhage, endophthalmitis, retinal detachment, and cataract, and clearly repeated injections can multiply the risk of these complications. Bevacizumab is used for the treatment of different ocular diseases. For improvement of drug availability after intravitreal administration, in this study, liposomal bevacizumab as a novel drug delivery system was prepared and compared with conventional formulas in the market.


METHODS
Bevacizumab was encapsulated into liposomes via the dehydration-rehydration method. After reducing the size of liposome to the nanoscale, the final liposomal formulation was tested in an animal model. Left eyes of rabbits received liposomal bevacizumab and the right eyes were injected by soluble bevacizumab. The free drug concentration in aqueous humor and vitreous samples at Days 3, 7, 14, 28, and 42 after the injection was determined by enzyme-linked immunosorbent assay.


RESULTS
Mean concentration of free bevacizumab in the eyes that received liposomal bevacizumab compared with the eyes injected with soluble bevacizumab was 1 (48 versus 28 microg/mL) and 5 (16 versus 3.3 microg/mL) times higher at Days 28 and 42, respectively. Mean concentration of free bevacizumab in the aqueous humor of both injected eyes was almost the same at the different intervals.


CONCLUSIONS
The results of this study showed the beneficial effects of liposomes in prolonging the residency of bevacizumab in the vitreous.
Abrishami
Majid
M
Khatam-al-Anbia Eye Hospital and Eye Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Zarei-Ghanavati
Siamak
S
Soroush
Dina
D
Rouhbakhsh
Majid
M
Jaafari
Mahmoud R
MR
Malaekeh-Nikouei
Bizhan
B
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D001082:Aqueous Humor / Q000378:metabolism; D000068258:Bevacizumab; D001682:Biological Availability; D002784:Cholesterol / Q000737:chemistry; D016503:Drug Delivery Systems; D004797:Enzyme-Linked Immunosorbent Assay; D007267:Injections; D008081:Liposomes; D010713:Phosphatidylcholines / Q000737:chemistry; D010767:Phosphorylcholine / Q000737:chemistry; D011817:Rabbits; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008081:Liposomes; D010713:Phosphatidylcholines; D042461:Vascular Endothelial Growth Factor A; D010767:Phosphorylcholine; D000068258:Bevacizumab; C038151:1,2-dipalmitoyl-sn-glycero-3-thiophosphocholine; D002784:Cholesterol